Genomic sequencing Examination of 733 HER2-amplified primary and metastatic breast tumours exposed important enrichment of mutations that activate RAS–MAPK signalling in advanced tumours handled with prior anti-HER2 therapies121. These mutations, together with NF1 and HER2 activating mutations, add to resistance to tucatinib and neratinib. The kind of tissue wherever your https://www.directivepublications.org/journal-of-clinical-breast-cancer/